[1]朱玉辉,柴 劲.黄芪补气汤联合还原型谷胱甘肽对肝癌介入治疗后患者肝功能、氧化应激及炎症的影响[J].陕西中医,2021,(5):570-572,576.[doi:DOI:10.3969/j.issn.1000-7369.2020.05.006]
　ZHU Yuhui,CHAI Jin.Effect of Huangqi Buqi decoction combined with reduced glutathione on liver function,oxidative stress and inflammation after interventional therapy for hepatocellular carcinoma[J].,2021,(5):570-572,576.[doi:DOI:10.3969/j.issn.1000-7369.2020.05.006]
点击复制

黄芪补气汤联合还原型谷胱甘肽对肝癌介入治疗后患者肝功能、氧化应激及炎症的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2021年5期
页码:
570-572,576
栏目:
临床研究
出版日期:
2021-05-05

文章信息/Info

Title:
Effect of Huangqi Buqi decoction combined with reduced glutathione on liver function,oxidative stress and inflammation after interventional therapy for hepatocellular carcinoma
作者:
朱玉辉; 柴 劲
(吉林大学第二医院,吉林 长春 130041)
Author(s):
ZHU Yuhui; CHAI Jin
(Second Hospital of Jilin University,Changchun 130041,China)
关键词:
肝癌;  黄芪补气汤;  还原型谷胱甘肽;  介入治疗;  总胆红素
Keywords:
Liver cancer;  Huangqi Buqi decoction;  Reduced glutathione;  Interventional therapy;  Total bilirubin
分类号:
R 735.7
DOI:
DOI:10.3969/j.issn.1000-7369.2020.05.006
文献标志码:
A
摘要:
目的:观察黄芪补气汤联合还原型谷胱甘肽对原发性肝癌(PLC)介入治疗后肝功能、氧化应激及炎症的影响。方法:选择PLC患者84例,随机分为对照组和观察组各42例。患者均给予肝动脉介入治疗,对照组术后给予还原型谷胱甘肽治疗,观察组在此基础上给予加味黄芪补气汤治疗。比较治疗前及4周后两组血清总胆红素(TBIL)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、碱性磷酸酶(ALP)、超氧化物歧化酶(SOD)、丙二醛(MDA)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)变化及总有效率,观察两组不良反应发生情况。结果:两组治疗前TBIL、ALT、AST、ALP、SOD、MDA、TNF-α、IL-6比较,差异无统计学意义(P>0.05); 治疗4周后,两组TBIL、ALT、AST、ALP、SOD均升高,MDA、TNF-α、IL-6均降低(P<0.05); 观察组治疗4周后SOD高于对照组,TBIL、ALT、AST、ALP、SOD、MDA、TNF-α、IL-6均低于对照组(P<0.05); 观察组总有效率高于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:黄芪补气汤联合还原型谷胱甘肽可明显改善经介入治疗后肝癌患者的肝功能、降低氧化应激及炎症反应水平。
Abstract:
Objective:To observe the effect of Huangqi Buqi decoction combined with reduced glutathione on liver function,oxidative stress and inflammation in patients with primary liver cancer(PLC)after interventional therapy.Methods:84 cases of PLC patients were selected.They were randomly divided into control group(n=42)and observation group(n=42).All patients were given hepatic artery interventional therapy,the control group was given reduced glutathione treatment after operation,and the observation group was given modified Huangqi Buqi decoction on the basis of the control group.The changes of serum TBIL,ALT,AST,ALP,SOD,MDA,TNF-α,IL-6 and the total effective rate were compared between the two groups before treatment and after 4 weeks.Results:There was no significant difference in TBIL,ALT,AST,ALP,SOD,MDA,TNF-α,IL-6 between the two groups before treatment(P>0.05).After 4 weeks of treatment,TBIL,ALT,AST,ALP,SOD in the two groups were increased,MDA,TNF-α,IL-6 were decreased(P<0.05); SOD in the observation group was higher than that in the control group,TBIL,ALT,AST,ALP,SOD,MDA,TNF-α,IL-6 were lower than those in the control group(P<0.05).The effective ratewas significantly higher than in the control group(P<0.05).There was no significant adverse reaction in both groups(P>0.05).Conclusion:Huangqi Buqi decoction combined with reduced glutathione can significantly improve liver function,reduce oxidative stress and inflammatory reaction in patients with liver cancer after interventional therapy.

参考文献/References:

[1] 祝普利,王德盛,田德福.肝动脉化疗栓塞联合射频消融治疗原发性肝癌124例临床观察[J].肝胆胰外科杂志,2018,30(1):1-4.
[2] 陈 嵩,吴志强,庄文权,等.经肝动脉栓塞术联合FOLFOX4方案持续动脉灌注化疗治疗肝细胞癌合并门静脉癌栓15例近期临床疗效评价[J].介入放射学杂志,2019,28(4):328-333.
[3] 张余黄,殷鹏飞.多烯磷脂酰胆碱联合还原型谷胱甘肽治疗酒精性肝炎效果观察[J].陕西医学杂志,2019,48(12):1715-1717.
[4] 张玉萍,李婵桂,邹 莹.黄芪四君子汤联合成分输血对肝癌介入术后免疫功能影响的研究[J].新中医,2020,52(9):54-56.
[5] 刘 慧,简洁雯.血清AFP、AFU、CA19-9联合检测在原发性肝癌诊断中的意义分析[J].中国卫生标准管理,2018,9(14):114-116.
[6] 中华人民共和国卫生和计划生育委员会.原发性肝癌诊疗规范(2017年版)[J].肿瘤综合治疗电子杂志,2017,3(4):14-30.
[7] Valery PC,Laversanne M,Clark PJ,et al.Projections of primary liver cancer to 2030 in 30 countries worldwide[J].Hepatology,2018,67(2):600-611.
[8] 李 珣,张祥林.肝动脉化疗栓塞联合恩替卡韦对原发性肝癌治疗效果及对患者血清中恶性肿瘤特异性生长因子的影响[J].陕西医学杂志,2019,48(7):873-875.
[9] 赖军明,胡 爽,林 红,等.重组人血管内皮抑制素联合TACE治疗中晚期原发性肝癌近期疗效的荟萃分析[J].中华肝胆外科杂志,2019,25(5):358-362.
[10] 李 娟,林志芳.异甘草酸镁对原发性肝癌肝动脉化疗栓塞术后炎症反应的影响及肝损伤的保护作用[J].中国现代普通外科进展,2020,23(3):66-68.
[11] 张 振,郜文辉,王亚琪,等.益气化瘀解毒方加减联合索拉非尼治疗原发性肝癌疗效研究[J].陕西中医,2019,40(3):352-354.
[12] 林栋毅,彭 波,郑景辉,等.基于肝癌临床特征构建的logistic回归模型对原发性肝癌中医证型的判断效能[J].临床肝胆病杂志,2020,36(6):1293-1298.
[13] 张 乔,李 静,张 琦,等.黄芪,苦参,皂角刺抗肝癌作用的比较研究[J].中医药信息,2020,37(1):48-54.
[14] 谌天娇,寇 敬,高淑慧,等.加味黄芪补气汤促进肿瘤患者外周血淋巴细胞增殖及活化的研究[J].中华中医药学刊,2017,36(3):605-608.
[15] 赵延军,单宇鹏.复方斑蝥胶囊对原发性肝癌患者介入治疗后细胞免疫功能的影响[J].陕西中医,2018,39(1):79-81.
[16] 李 娟,何 娟,毛恩强,等.还原型谷胱甘肽对重症患者使用万古霉素致药物性肾损伤的保护作用[J].中华危重病急救医学,2020,32(7):819-823.
[17] 李志路,赵 勇,乔喜婷,等.TACE、PSE联合活血化瘀中药治疗原发性肝癌合并脾功能亢进的疗效观察[J].现代中西医结合杂志,2018,27(27):3015-3018.
[18] 曾德创,陈宏明,潘兴寿,等.石斛多糖对SHR氧化应激反应和晚期糖基化终产物代谢的影响[J].右江医学,2019,47(9):647-652.
[19] 张芝华,李淑荣,马桂勇,等.岩黄连注射液联合TACE对中晚期肝癌患者炎性反应,氧化应激的影响[J].河北医药,2020,42(7):95-98.
[20] 王 瑛,袁鹤立,袁 楠,等.清热利胆方对原发性肝癌患者TACE联合MWA术后免疫细胞及炎症递质的影响[J].河北联合大学学报:医学版,2020,22(2):105-113.

相似文献/References:

[1]肖 岚,朱 宏,张 婷,等.董克礼教授治疗原发性肝癌临床经验*[J].陕西中医,2020,(11):1639.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.032]
　XIAO Lan,ZHU Hong,ZHANG Ting,et al.Experience of professor DONG Keli for treating primary liver cancer[J].,2020,(5):1639.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.032]
[2]王 军,徐建良,杜燕红.扶正祛邪汤对肝癌模型大鼠肠道菌群微生态环境的作用研究[J].陕西中医,2021,(2):143.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.002]
　WANG Jun,XU Jianliang,DU Yanhong.Effect of Fuzheng Quxie decoction on intestinal microflora microecological environment of liver cancer model rats[J].,2021,(5):143.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.002]
[3]刘振方,孙巧玉,孟祥彩,等.黄芩素下调微小RNA-130a抑制肝癌细胞侵袭机制研究[J].陕西中医,2021,(12):1667.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.003]
　LIU Zhenfang,SUN Qiaoyu,MENG Xiangcai,et al.Study on mechanism of baicalein down-regulating miR-130a to inhibit hepatocellular carcinoma invasion[J].,2021,(5):1667.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.003]
[4]李武浩,许尤琪.中医药防治肝动脉灌注化疗相关不良反应研究进展[J].陕西中医,2022,(5):673.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.031]
　LI Wuhao,XU Youqi.Clinical research progress of traditional Chinese medicine on the prevention and treatment of related adverse reaction of hepatic artery infusion chemotherapy[J].,2022,(5):673.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.031]
[5]陈 嵘,李淑敏,李旭华,等.软坚散结方调控小鼠HIF-1α 糖酵解分子转导抑制肝肿瘤细胞增殖机制研究[J].陕西中医,2023,(7):839.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.003]
　CHEN Rong,LI Shumin,LI Xuhua,et al.Mechanism study on Ruanjian Sanjie prescription inhibit proliferation of liver cancer cells through regulating HIF-1α pathway[J].,2023,(5):839.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.003]
[6]刘 鹏,陈青山,杨建波.柴胡疏肝散加减联合射频消融治疗肝癌疗效研究[J].陕西中医,2023,(7):892.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.015]
　LIU Peng,CHEN Qingshan,YANG Jianbo.Curative effect study on Chaihu Shugan powder combined with radiofrequency ablation for liver cancer[J].,2023,(5):892.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.015]
[7]张宏生,林月洁,陆凤娟.血府逐瘀汤加减联合盐酸吗啡缓释片治疗肝癌疼痛瘀血内阻证疗效研究[J].陕西中医,2023,(7):897.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.016]
　ZHANG Hongsheng,LIN Yuejie,LU Fengjuan.Clinical study on modified Xuefu Zhuyu decoction supplemented with morphine hydrochloride sustained-release tablets in treatment of liver cancer pain of Yuxue Neizu syndrome[J].,2023,(5):897.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.016]
[8]孔庆旭,陈桂云,陈自力,等.槲芪方加减对肝癌化疗栓塞术后大鼠一氧化氮合酶、血管内皮生长因子、乏氧及免疫功能的影响[J].陕西中医,2024,(2):181.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.007]
　KONG Qingxu,CHEN Guiyun,CHEN Zili,et al.Effects of Huqi formula on iNOS,VEGF,hypoxia and immune function of rats after chemoembolization for liver cancer[J].,2024,(5):181.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.007]
[9]郭桓博,马瑞雪,朱正望,等.中药基于铁死亡机制防治肝癌研究进展[J].陕西中医,2024,(2):282.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.030]
　GUO Huanbo,MA Ruixue,ZHU Zhengwang,et al.Research progress in the prevention and treatment of liver cancer based on the mechanism of iron osis in traditional Chinese medicine[J].,2024,(5):282.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.030]
[10]李杳瑶,刘 华,孙铜林,等.鳖甲煎丸对肝癌大鼠黏着斑激酶/雷帕霉素靶蛋白通路的影响[J].陕西中医,2024,(3):308.[doi:DOI:10.3969/j.issn.1000-7369.2024.03.004]
　LI Yaoyao,LIU Hua,SUN Tonglin,et al.Effects of Biejia Jianwan on liver histopathological features and FAK/mTORC1 pathway in rats with hepatocellular carcinoma[J].,2024,(5):308.[doi:DOI:10.3969/j.issn.1000-7369.2024.03.004]

备注/Memo

备注/Memo:
基金项目:国家科技支撑科研项目(1909LN52)
更新日期/Last Update: 2021-05-10